#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Attenuated Resting-State Functional Connectivity in Patients with Childhood- and Adult-Onset Schizophrenia Background Childhood-onset schizophrenia (COS) is a rare, severe form of the adult-onset disorder (AOS).
1-1	0-10	Attenuated	_
1-2	11-24	Resting-State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-3	25-35	Functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-4	36-48	Connectivity	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-5	49-51	in	_
1-6	52-60	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-7	61-65	with	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-8	66-76	Childhood-	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-9	77-80	and	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-10	81-92	Adult-Onset	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
1-11	93-106	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
1-12	107-117	Background	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
1-13	118-133	Childhood-onset	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
1-14	134-147	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
1-15	148-149	(	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
1-16	150-153	COS	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
1-17	154-155	)	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
1-18	156-158	is	_
1-19	159-160	a	_
1-20	161-165	rare	_
1-21	166-167	,	_
1-22	168-174	severe	_
1-23	175-179	form	_
1-24	180-182	of	_
1-25	183-186	the	_
1-26	187-198	adult-onset	http://maven.renci.org/NeuroBridge/neurobridge#ConductDisorder
1-27	199-207	disorder	http://maven.renci.org/NeuroBridge/neurobridge#ConductDisorder
1-28	208-209	(	http://maven.renci.org/NeuroBridge/neurobridge#ConductDisorder
1-29	210-213	AOS	http://maven.renci.org/NeuroBridge/neurobridge#ConductDisorder
1-30	214-215	)	http://maven.renci.org/NeuroBridge/neurobridge#ConductDisorder
1-31	216-217	.	_

Text=Our previous resting-state fMRI study identified attenuated functional connectivity in COS compared with controls.
2-1	218-221	Our	_
2-2	222-230	previous	_
2-3	231-244	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-4	245-249	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-5	250-255	study	_
2-6	256-266	identified	_
2-7	267-277	attenuated	_
2-8	278-288	functional	_
2-9	289-301	connectivity	_
2-10	302-304	in	_
2-11	305-308	COS	http://maven.renci.org/NeuroBridge/neurobridge#Glucose
2-12	309-317	compared	_
2-13	318-322	with	_
2-14	323-331	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-15	332-333	.	_

Text=Here, we ask whether COS and AOS patients and their siblings exhibit similar abnormalities of functional connectivity.
3-1	334-338	Here	_
3-2	339-340	,	_
3-3	341-343	we	_
3-4	344-347	ask	_
3-5	348-355	whether	_
3-6	356-359	COS	http://maven.renci.org/NeuroBridge/neurobridge#Glucose
3-7	360-363	and	_
3-8	364-367	AOS	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-9	368-376	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-10	377-380	and	_
3-11	381-386	their	_
3-12	387-395	siblings	_
3-13	396-403	exhibit	_
3-14	404-411	similar	_
3-15	412-425	abnormalities	_
3-16	426-428	of	_
3-17	429-439	functional	_
3-18	440-452	connectivity	_
3-19	453-454	.	_

Text=Methods A whole-brain, data-driven approach was used to assess resting-state functional connectivity differences in COS (patients/siblings/controls, n: 26/28/33) and AOS (n: 19/28/30).
4-1	455-462	Methods	_
4-2	463-464	A	_
4-3	465-476	whole-brain	_
4-4	477-478	,	_
4-5	479-490	data-driven	_
4-6	491-499	approach	_
4-7	500-503	was	_
4-8	504-508	used	_
4-9	509-511	to	_
4-10	512-518	assess	_
4-11	519-532	resting-state	_
4-12	533-543	functional	_
4-13	544-556	connectivity	_
4-14	557-568	differences	_
4-15	569-571	in	_
4-16	572-575	COS	_
4-17	576-577	(	_
4-18	578-604	patients/siblings/controls	_
4-19	605-606	,	_
4-20	607-608	n	_
4-21	609-610	:	_
4-22	611-619	26/28/33	_
4-23	620-621	)	_
4-24	622-625	and	_
4-25	626-629	AOS	_
4-26	630-631	(	_
4-27	632-633	n	_
4-28	634-635	:	_
4-29	636-644	19/28/30	_
4-30	645-646	)	_
4-31	647-648	.	_

Text=There were no significant differences in age, sex, or head motion across groups in each dataset and as designed, the COS dataset has a significantly lower age than the AOS.
5-1	649-654	There	_
5-2	655-659	were	_
5-3	660-662	no	_
5-4	663-674	significant	_
5-5	675-686	differences	_
5-6	687-689	in	_
5-7	690-693	age	_
5-8	694-695	,	_
5-9	696-699	sex	_
5-10	700-701	,	_
5-11	702-704	or	_
5-12	705-709	head	_
5-13	710-716	motion	_
5-14	717-723	across	_
5-15	724-730	groups	_
5-16	731-733	in	_
5-17	734-738	each	_
5-18	739-746	dataset	_
5-19	747-750	and	_
5-20	751-753	as	_
5-21	754-762	designed	_
5-22	763-764	,	_
5-23	765-768	the	_
5-24	769-772	COS	_
5-25	773-780	dataset	_
5-26	781-784	has	_
5-27	785-786	a	_
5-28	787-800	significantly	_
5-29	801-806	lower	_
5-30	807-810	age	_
5-31	811-815	than	_
5-32	816-819	the	_
5-33	820-823	AOS	_
5-34	824-825	.	_

Text=Results Both COS and AOS patients showed decreased functional connectivity relative to controls among a wide set of brain regions (P <0.05, corrected), but their siblings did not.
6-1	826-833	Results	_
6-2	834-838	Both	_
6-3	839-842	COS	http://maven.renci.org/NeuroBridge/neurobridge#Glucose
6-4	843-846	and	_
6-5	847-850	AOS	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-6	851-859	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-7	860-866	showed	_
6-8	867-876	decreased	_
6-9	877-887	functional	_
6-10	888-900	connectivity	_
6-11	901-909	relative	_
6-12	910-912	to	_
6-13	913-921	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-14	922-927	among	_
6-15	928-929	a	_
6-16	930-934	wide	_
6-17	935-938	set	_
6-18	939-941	of	_
6-19	942-947	brain	_
6-20	948-955	regions	_
6-21	956-957	(	_
6-22	958-959	P	_
6-23	960-961	<	_
6-24	962-966	0.05	_
6-25	967-968	,	_
6-26	969-978	corrected	_
6-27	979-980	)	_
6-28	981-982	,	_
6-29	983-986	but	_
6-30	987-992	their	_
6-31	993-1001	siblings	_
6-32	1002-1005	did	_
6-33	1006-1009	not	_
6-34	1010-1011	.	_

Text=Decreased connectivity in COS and AOS patients showed no amplitude differences and was not modulated by age-at-onset or medication doses.
7-1	1012-1021	Decreased	_
7-2	1022-1034	connectivity	_
7-3	1035-1037	in	_
7-4	1038-1041	COS	http://maven.renci.org/NeuroBridge/neurobridge#Glucose
7-5	1042-1045	and	_
7-6	1046-1049	AOS	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-7	1050-1058	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-8	1059-1065	showed	_
7-9	1066-1068	no	_
7-10	1069-1078	amplitude	_
7-11	1079-1090	differences	_
7-12	1091-1094	and	_
7-13	1095-1098	was	_
7-14	1099-1102	not	_
7-15	1103-1112	modulated	_
7-16	1113-1115	by	_
7-17	1116-1128	age-at-onset	_
7-18	1129-1131	or	_
7-19	1132-1142	medication	_
7-20	1143-1148	doses	_
7-21	1149-1150	.	_

Text=Cluster analysis revealed that these regions fell into two large-scale networks: one sensorimotor network and one centered on default-mode network regions, but including higher-order cognitive areas only in COS.
8-1	1151-1158	Cluster	_
8-2	1159-1167	analysis	_
8-3	1168-1176	revealed	_
8-4	1177-1181	that	_
8-5	1182-1187	these	_
8-6	1188-1195	regions	_
8-7	1196-1200	fell	_
8-8	1201-1205	into	_
8-9	1206-1209	two	_
8-10	1210-1221	large-scale	_
8-11	1222-1230	networks	_
8-12	1231-1232	:	_
8-13	1233-1236	one	_
8-14	1237-1249	sensorimotor	_
8-15	1250-1257	network	_
8-16	1258-1261	and	_
8-17	1262-1265	one	_
8-18	1266-1274	centered	_
8-19	1275-1277	on	_
8-20	1278-1290	default-mode	_
8-21	1291-1298	network	_
8-22	1299-1306	regions	_
8-23	1307-1308	,	_
8-24	1309-1312	but	_
8-25	1313-1322	including	_
8-26	1323-1335	higher-order	_
8-27	1336-1345	cognitive	_
8-28	1346-1351	areas	_
8-29	1352-1356	only	_
8-30	1357-1359	in	_
8-31	1360-1363	COS	_
8-32	1364-1365	.	_

Text=Decreased connectivity between these two networks was notable (P <0.05, corrected) for both patient groups.
9-1	1366-1375	Decreased	_
9-2	1376-1388	connectivity	_
9-3	1389-1396	between	_
9-4	1397-1402	these	_
9-5	1403-1406	two	_
9-6	1407-1415	networks	_
9-7	1416-1419	was	_
9-8	1420-1427	notable	_
9-9	1428-1429	(	_
9-10	1430-1431	P	_
9-11	1432-1433	<	_
9-12	1434-1438	0.05	_
9-13	1439-1440	,	_
9-14	1441-1450	corrected	_
9-15	1451-1452	)	_
9-16	1453-1456	for	_
9-17	1457-1461	both	_
9-18	1462-1469	patient	_
9-19	1470-1476	groups	_
9-20	1477-1478	.	_

Text=Conclusions A shared pattern of attenuated functional connectivity was found in COS and AOS, supporting the continuity of childhood-onset and adult-onset schizophrenia.
10-1	1479-1490	Conclusions	_
10-2	1491-1492	A	_
10-3	1493-1499	shared	_
10-4	1500-1507	pattern	_
10-5	1508-1510	of	_
10-6	1511-1521	attenuated	_
10-7	1522-1532	functional	_
10-8	1533-1545	connectivity	_
10-9	1546-1549	was	_
10-10	1550-1555	found	_
10-11	1556-1558	in	_
10-12	1559-1562	COS	http://maven.renci.org/NeuroBridge/neurobridge#Glucose
10-13	1563-1566	and	_
10-14	1567-1570	AOS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-15	1571-1572	,	_
10-16	1573-1583	supporting	_
10-17	1584-1587	the	_
10-18	1588-1598	continuity	_
10-19	1599-1601	of	_
10-20	1602-1617	childhood-onset	_
10-21	1618-1621	and	_
10-22	1622-1633	adult-onset	_
10-23	1634-1647	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-24	1648-1649	.	_

Text=Connections were altered between sensorimotor areas and default-mode areas in both COS and AOS, suggesting potential abnormalities in processes of self-monitoring and sensory prediction.
11-1	1650-1661	Connections	_
11-2	1662-1666	were	_
11-3	1667-1674	altered	_
11-4	1675-1682	between	_
11-5	1683-1695	sensorimotor	_
11-6	1696-1701	areas	_
11-7	1702-1705	and	_
11-8	1706-1718	default-mode	_
11-9	1719-1724	areas	_
11-10	1725-1727	in	_
11-11	1728-1732	both	_
11-12	1733-1736	COS	_
11-13	1737-1740	and	_
11-14	1741-1744	AOS	_
11-15	1745-1746	,	_
11-16	1747-1757	suggesting	_
11-17	1758-1767	potential	_
11-18	1768-1781	abnormalities	_
11-19	1782-1784	in	_
11-20	1785-1794	processes	_
11-21	1795-1797	of	_
11-22	1798-1813	self-monitoring	_
11-23	1814-1817	and	_
11-24	1818-1825	sensory	_
11-25	1826-1836	prediction	_
11-26	1837-1838	.	_

Text=The absence of substantial dysconnectivity in siblings indicates that attenuation is state-related.
12-1	1839-1842	The	_
12-2	1843-1850	absence	_
12-3	1851-1853	of	_
12-4	1854-1865	substantial	_
12-5	1866-1881	dysconnectivity	_
12-6	1882-1884	in	_
12-7	1885-1893	siblings	_
12-8	1894-1903	indicates	_
12-9	1904-1908	that	_
12-10	1909-1920	attenuation	_
12-11	1921-1923	is	_
12-12	1924-1937	state-related	_
12-13	1938-1939	.	_

Text=2 Methods 2.1 Participants Twenty-six individuals with childhood-onset schizophrenia (COS), 28 nonpsychotic siblings of individuals with COS (COS_SIB), and 33 typically developing controls (COS_CON) participated in the COS study (Table 1).
13-1	1940-1941	2	_
13-2	1942-1949	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
13-3	1950-1953	2.1	_
13-4	1954-1966	Participants	_
13-5	1967-1977	Twenty-six	_
13-6	1978-1989	individuals	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
13-7	1990-1994	with	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
13-8	1995-2010	childhood-onset	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
13-9	2011-2024	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
13-10	2025-2026	(	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
13-11	2027-2030	COS	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
13-12	2031-2032	)	http://maven.renci.org/NeuroBridge/neurobridge#LateOnsetSchizophrenia
13-13	2033-2034	,	_
13-14	2035-2037	28	_
13-15	2038-2050	nonpsychotic	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-16	2051-2059	siblings	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-17	2060-2062	of	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-18	2063-2074	individuals	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-19	2075-2079	with	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-20	2080-2083	COS	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-21	2084-2085	(	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-22	2086-2093	COS_SIB	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-23	2094-2095	)	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-24	2096-2097	,	_
13-25	2098-2101	and	_
13-26	2102-2104	33	_
13-27	2105-2114	typically	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-28	2115-2125	developing	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-29	2126-2134	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-30	2135-2136	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-31	2137-2144	COS_CON	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-32	2145-2146	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-33	2147-2159	participated	_
13-34	2160-2162	in	_
13-35	2163-2166	the	_
13-36	2167-2170	COS	http://maven.renci.org/NeuroBridge/neurobridge#Glucose
13-37	2171-2176	study	_
13-38	2177-2178	(	_
13-39	2179-2184	Table	_
13-40	2185-2186	1	_
13-41	2187-2188	)	_
13-42	2189-2190	.	_

Text=Some of the included COS patients and siblings were related.
14-1	2191-2195	Some	_
14-2	2196-2198	of	_
14-3	2199-2202	the	_
14-4	2203-2211	included	_
14-5	2212-2215	COS	http://maven.renci.org/NeuroBridge/neurobridge#Glucose
14-6	2216-2224	patients	_
14-7	2225-2228	and	_
14-8	2229-2237	siblings	_
14-9	2238-2242	were	_
14-10	2243-2250	related	_
14-11	2251-2252	.	_

Text=Informed assent and consent were obtained from all participants and their parent/guardian as applicable in accordance with a National Institutes of Health Institutional Review Board approved protocol.
15-1	2253-2261	Informed	_
15-2	2262-2268	assent	_
15-3	2269-2272	and	_
15-4	2273-2280	consent	_
15-5	2281-2285	were	_
15-6	2286-2294	obtained	_
15-7	2295-2299	from	_
15-8	2300-2303	all	_
15-9	2304-2316	participants	_
15-10	2317-2320	and	_
15-11	2321-2326	their	_
15-12	2327-2342	parent/guardian	_
15-13	2343-2345	as	_
15-14	2346-2356	applicable	_
15-15	2357-2359	in	_
15-16	2360-2370	accordance	_
15-17	2371-2375	with	_
15-18	2376-2377	a	_
15-19	2378-2386	National	_
15-20	2387-2397	Institutes	_
15-21	2398-2400	of	_
15-22	2401-2407	Health	_
15-23	2408-2421	Institutional	_
15-24	2422-2428	Review	_
15-25	2429-2434	Board	_
15-26	2435-2443	approved	_
15-27	2444-2452	protocol	_
15-28	2453-2454	.	_

Text=COS participants were recruited nationwide and diagnosed after inpatient observation that included medication washout when clinically appropriate.
16-1	2455-2458	COS	http://maven.renci.org/NeuroBridge/neurobridge#Glucose
16-2	2459-2471	participants	_
16-3	2472-2476	were	_
16-4	2477-2486	recruited	_
16-5	2487-2497	nationwide	_
16-6	2498-2501	and	_
16-7	2502-2511	diagnosed	_
16-8	2512-2517	after	_
16-9	2518-2527	inpatient	_
16-10	2528-2539	observation	_
16-11	2540-2544	that	_
16-12	2545-2553	included	_
16-13	2554-2564	medication	_
16-14	2565-2572	washout	_
16-15	2573-2577	when	_
16-16	2578-2588	clinically	_
16-17	2589-2600	appropriate	_
16-18	2601-2602	.	_

Text=Exclusionary criteria included medical or neurological illness, substance abuse, or full-scale IQ below 70 prior to onset of psychotic symptoms (for further details, see McKenna et al .).
17-1	2603-2615	Exclusionary	_
17-2	2616-2624	criteria	_
17-3	2625-2633	included	_
17-4	2634-2641	medical	_
17-5	2642-2644	or	_
17-6	2645-2657	neurological	_
17-7	2658-2665	illness	_
17-8	2666-2667	,	_
17-9	2668-2677	substance	_
17-10	2678-2683	abuse	_
17-11	2684-2685	,	_
17-12	2686-2688	or	_
17-13	2689-2699	full-scale	_
17-14	2700-2702	IQ	_
17-15	2703-2708	below	_
17-16	2709-2711	70	_
17-17	2712-2717	prior	_
17-18	2718-2720	to	_
17-19	2721-2726	onset	_
17-20	2727-2729	of	_
17-21	2730-2739	psychotic	_
17-22	2740-2748	symptoms	_
17-23	2749-2750	(	_
17-24	2751-2754	for	_
17-25	2755-2762	further	_
17-26	2763-2770	details	_
17-27	2771-2772	,	_
17-28	2773-2776	see	_
17-29	2777-2784	McKenna	_
17-30	2785-2787	et	_
17-31	2788-2790	al	_
17-32	2791-2792	.	_
17-33	2793-2794	)	_
17-34	2795-2796	.	_

Text=Control participants were free of lifetime medical or psychiatric disorders as determined by clinical examination and standardized interview, and none had psychiatric illness in a first-degree relative.
18-1	2797-2804	Control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
18-2	2805-2817	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
18-3	2818-2822	were	_
18-4	2823-2827	free	_
18-5	2828-2830	of	_
18-6	2831-2839	lifetime	_
18-7	2840-2847	medical	_
18-8	2848-2850	or	_
18-9	2851-2862	psychiatric	_
18-10	2863-2872	disorders	_
18-11	2873-2875	as	_
18-12	2876-2886	determined	_
18-13	2887-2889	by	_
18-14	2890-2898	clinical	_
18-15	2899-2910	examination	_
18-16	2911-2914	and	_
18-17	2915-2927	standardized	_
18-18	2928-2937	interview	_
18-19	2938-2939	,	_
18-20	2940-2943	and	_
18-21	2944-2948	none	_
18-22	2949-2952	had	_
18-23	2953-2964	psychiatric	_
18-24	2965-2972	illness	_
18-25	2973-2975	in	_
18-26	2976-2977	a	_
18-27	2978-2990	first-degree	_
18-28	2991-2999	relative	_
18-29	3000-3001	.	_

Text=All COS patients were rated by staff clinicians using the Scale for the Assessment of Positive Symptoms (SAPS) and Scale for the Assessment of Negative Symptoms (SANS) for quantification of symptom severity.
19-1	3002-3005	All	_
19-2	3006-3009	COS	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-3	3010-3018	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-4	3019-3023	were	_
19-5	3024-3029	rated	_
19-6	3030-3032	by	_
19-7	3033-3038	staff	_
19-8	3039-3049	clinicians	_
19-9	3050-3055	using	_
19-10	3056-3059	the	_
19-11	3060-3065	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-12	3066-3069	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-13	3070-3073	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-14	3074-3084	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-15	3085-3087	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-16	3088-3096	Positive	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-17	3097-3105	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-18	3106-3107	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-19	3108-3112	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-20	3113-3114	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-21	3115-3118	and	_
19-22	3119-3124	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-23	3125-3128	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-24	3129-3132	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-25	3133-3143	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-26	3144-3146	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-27	3147-3155	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-28	3156-3164	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-29	3165-3166	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-30	3167-3171	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-31	3172-3173	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
19-32	3174-3177	for	_
19-33	3178-3192	quantification	_
19-34	3193-3195	of	_
19-35	3196-3203	symptom	_
19-36	3204-3212	severity	_
19-37	3213-3214	.	_

Text=All COS patients were receiving treatment with antipsychotic medication at the time of the study, typically clozapine, and had been stabilized for at least 2 weeks.
20-1	3215-3218	All	_
20-2	3219-3222	COS	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-3	3223-3231	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-4	3232-3236	were	_
20-5	3237-3246	receiving	_
20-6	3247-3256	treatment	_
20-7	3257-3261	with	_
20-8	3262-3275	antipsychotic	_
20-9	3276-3286	medication	_
20-10	3287-3289	at	_
20-11	3290-3293	the	_
20-12	3294-3298	time	_
20-13	3299-3301	of	_
20-14	3302-3305	the	_
20-15	3306-3311	study	_
20-16	3312-3313	,	_
20-17	3314-3323	typically	_
20-18	3324-3333	clozapine	_
20-19	3334-3335	,	_
20-20	3336-3339	and	_
20-21	3340-3343	had	_
20-22	3344-3348	been	_
20-23	3349-3359	stabilized	_
20-24	3360-3363	for	_
20-25	3364-3366	at	_
20-26	3367-3372	least	_
20-27	3373-3374	2	_
20-28	3375-3380	weeks	_
20-29	3381-3382	.	_

Text=The participants for the AOS study (Table 1) were the same set as reported in Repovs et al.
21-1	3383-3386	The	_
21-2	3387-3399	participants	_
21-3	3400-3403	for	_
21-4	3404-3407	the	_
21-5	3408-3411	AOS	_
21-6	3412-3417	study	_
21-7	3418-3419	(	_
21-8	3420-3425	Table	_
21-9	3426-3427	1	_
21-10	3428-3429	)	_
21-11	3430-3434	were	_
21-12	3435-3438	the	_
21-13	3439-3443	same	_
21-14	3444-3447	set	_
21-15	3448-3450	as	_
21-16	3451-3459	reported	_
21-17	3460-3462	in	_
21-18	3463-3469	Repovs	_
21-19	3470-3472	et	_
21-20	3473-3475	al	_
21-21	3476-3477	.	_

Text=but 12 participants were excluded to match groups for motion and age; see Supplemental Image Preprocessing for details.
22-1	3478-3481	but	_
22-2	3482-3484	12	_
22-3	3485-3497	participants	_
22-4	3498-3502	were	_
22-5	3503-3511	excluded	_
22-6	3512-3514	to	_
22-7	3515-3520	match	_
22-8	3521-3527	groups	_
22-9	3528-3531	for	_
22-10	3532-3538	motion	_
22-11	3539-3542	and	_
22-12	3543-3546	age	_
22-13	3547-3548	;	_
22-14	3549-3552	see	_
22-15	3553-3565	Supplemental	_
22-16	3566-3571	Image	_
22-17	3572-3585	Preprocessing	_
22-18	3586-3589	for	_
22-19	3590-3597	details	_
22-20	3598-3599	.	_

Text=Sex and other demographic variables were still matched across groups.
23-1	3600-3603	Sex	_
23-2	3604-3607	and	_
23-3	3608-3613	other	_
23-4	3614-3625	demographic	_
23-5	3626-3635	variables	_
23-6	3636-3640	were	_
23-7	3641-3646	still	_
23-8	3647-3654	matched	_
23-9	3655-3661	across	_
23-10	3662-3668	groups	_
23-11	3669-3670	.	_

Text=These participants were recruited through the Conte Center for the Neuroscience of Mental Disorders at Washington University School of Medicine in St. Louis and included: 1) 19 individuals with DSM-IV schizophrenia (AOS); 2) 28 nonpsychotic siblings of individuals with schizophrenia (AOS_SIB); 3) 30 healthy control subjects (AOS_CON).
24-1	3671-3676	These	_
24-2	3677-3689	participants	_
24-3	3690-3694	were	_
24-4	3695-3704	recruited	_
24-5	3705-3712	through	_
24-6	3713-3716	the	_
24-7	3717-3722	Conte	_
24-8	3723-3729	Center	_
24-9	3730-3733	for	_
24-10	3734-3737	the	_
24-11	3738-3750	Neuroscience	_
24-12	3751-3753	of	_
24-13	3754-3760	Mental	_
24-14	3761-3770	Disorders	_
24-15	3771-3773	at	_
24-16	3774-3784	Washington	_
24-17	3785-3795	University	_
24-18	3796-3802	School	_
24-19	3803-3805	of	_
24-20	3806-3814	Medicine	_
24-21	3815-3817	in	_
24-22	3818-3821	St.	_
24-23	3822-3827	Louis	_
24-24	3828-3831	and	_
24-25	3832-3840	included	_
24-26	3841-3842	:	_
24-27	3843-3844	1	_
24-28	3845-3846	)	_
24-29	3847-3849	19	_
24-30	3850-3861	individuals	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-31	3862-3866	with	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-32	3867-3873	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-33	3874-3887	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-34	3888-3889	(	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-35	3890-3893	AOS	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-36	3894-3895	)	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-37	3896-3897	;	_
24-38	3898-3899	2	_
24-39	3900-3901	)	_
24-40	3902-3904	28	_
24-41	3905-3917	nonpsychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
24-42	3918-3926	siblings	_
24-43	3927-3929	of	_
24-44	3930-3941	individuals	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-45	3942-3946	with	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-46	3947-3960	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-47	3961-3962	(	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-48	3963-3970	AOS_SIB	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-49	3971-3972	)	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
24-50	3973-3974	;	_
24-51	3975-3976	3	_
24-52	3977-3978	)	_
24-53	3979-3981	30	_
24-54	3982-3989	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
24-55	3990-3997	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
24-56	3998-4006	subjects	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
24-57	4007-4008	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
24-58	4009-4016	AOS_CON	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
24-59	4017-4018	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
24-60	4019-4020	.	_

Text=Some of the AOS patients and siblings were related.
25-1	4021-4025	Some	_
25-2	4026-4028	of	_
25-3	4029-4032	the	_
25-4	4033-4036	AOS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
25-5	4037-4045	patients	_
25-6	4046-4049	and	_
25-7	4050-4058	siblings	_
25-8	4059-4063	were	_
25-9	4064-4071	related	_
25-10	4072-4073	.	_

Text=All participants gave written informed consent for participation.
26-1	4074-4077	All	_
26-2	4078-4090	participants	_
26-3	4091-4095	gave	_
26-4	4096-4103	written	_
26-5	4104-4112	informed	_
26-6	4113-4120	consent	_
26-7	4121-4124	for	_
26-8	4125-4138	participation	_
26-9	4139-4140	.	_

Text=Subjects were diagnosed using a semi-structured interview and the Structured Clinical Interview for DSM-IV Axis I Disorders.
27-1	4141-4149	Subjects	_
27-2	4150-4154	were	_
27-3	4155-4164	diagnosed	_
27-4	4165-4170	using	_
27-5	4171-4172	a	_
27-6	4173-4188	semi-structured	_
27-7	4189-4198	interview	_
27-8	4199-4202	and	_
27-9	4203-4206	the	_
27-10	4207-4217	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-11	4218-4226	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-12	4227-4236	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-13	4237-4240	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-14	4241-4247	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-15	4248-4252	Axis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-16	4253-4254	I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-17	4255-4264	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-18	4265-4266	.	_

Text=Participants were excluded for substance dependence/abuse within the last 6 months; medical illness; history of head injury; or mental retardation (diagnostic and exclusion details elsewhere).
28-1	4267-4279	Participants	_
28-2	4280-4284	were	_
28-3	4285-4293	excluded	_
28-4	4294-4297	for	_
28-5	4298-4307	substance	_
28-6	4308-4324	dependence/abuse	_
28-7	4325-4331	within	_
28-8	4332-4335	the	_
28-9	4336-4340	last	_
28-10	4341-4342	6	_
28-11	4343-4349	months	_
28-12	4350-4351	;	_
28-13	4352-4359	medical	_
28-14	4360-4367	illness	_
28-15	4368-4369	;	_
28-16	4370-4377	history	_
28-17	4378-4380	of	_
28-18	4381-4385	head	_
28-19	4386-4392	injury	_
28-20	4393-4394	;	_
28-21	4395-4397	or	_
28-22	4398-4404	mental	_
28-23	4405-4416	retardation	_
28-24	4417-4418	(	_
28-25	4419-4429	diagnostic	_
28-26	4430-4433	and	_
28-27	4434-4443	exclusion	_
28-28	4444-4451	details	_
28-29	4452-4461	elsewhere	_
28-30	4462-4463	)	_
28-31	4464-4465	.	_

Text=The AOS patients were all outpatients and had been stabilized on antipsychotic medication for at least 2 weeks.
29-1	4466-4469	The	_
29-2	4470-4473	AOS	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
29-3	4474-4482	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
29-4	4483-4487	were	_
29-5	4488-4491	all	_
29-6	4492-4503	outpatients	_
29-7	4504-4507	and	_
29-8	4508-4511	had	_
29-9	4512-4516	been	_
29-10	4517-4527	stabilized	_
29-11	4528-4530	on	_
29-12	4531-4544	antipsychotic	_
29-13	4545-4555	medication	_
29-14	4556-4559	for	_
29-15	4560-4562	at	_
29-16	4563-4568	least	_
29-17	4569-4570	2	_
29-18	4571-4576	weeks	_
29-19	4577-4578	.	_

Text=Control subjects had no lifetime history of Axis I psychotic or mood disorders and no first-degree relatives with a psychotic disorder.
30-1	4579-4586	Control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
30-2	4587-4595	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
30-3	4596-4599	had	_
30-4	4600-4602	no	_
30-5	4603-4611	lifetime	_
30-6	4612-4619	history	_
30-7	4620-4622	of	_
30-8	4623-4627	Axis	_
30-9	4628-4629	I	_
30-10	4630-4639	psychotic	_
30-11	4640-4642	or	_
30-12	4643-4647	mood	_
30-13	4648-4657	disorders	_
30-14	4658-4661	and	_
30-15	4662-4664	no	_
30-16	4665-4677	first-degree	_
30-17	4678-4687	relatives	_
30-18	4688-4692	with	_
30-19	4693-4694	a	_
30-20	4695-4704	psychotic	_
30-21	4705-4713	disorder	_
30-22	4714-4715	.	_

Text=All patients were assessed using the SAPS and SANS by a master ’ s-level research assistant who regularly participated in training and reliability sessions.
31-1	4716-4719	All	_
31-2	4720-4728	patients	_
31-3	4729-4733	were	_
31-4	4734-4742	assessed	_
31-5	4743-4748	using	_
31-6	4749-4752	the	_
31-7	4753-4757	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
31-8	4758-4761	and	_
31-9	4762-4766	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
31-10	4767-4769	by	_
31-11	4770-4771	a	_
31-12	4772-4778	master	_
31-13	4779-4780	’	_
31-14	4781-4788	s-level	_
31-15	4789-4797	research	_
31-16	4798-4807	assistant	_
31-17	4808-4811	who	_
31-18	4812-4821	regularly	_
31-19	4822-4834	participated	_
31-20	4835-4837	in	_
31-21	4838-4846	training	_
31-22	4847-4850	and	_
31-23	4851-4862	reliability	_
31-24	4863-4871	sessions	_
31-25	4872-4873	.	_

Text=2.2 Image Acquisition For each participant, resting state EPI (echo-planar-imaging) images were acquired; parameters varied between COS and AOS data, including make of scanner (see Table S1 for details).
32-1	4874-4877	2.2	_
32-2	4878-4883	Image	_
32-3	4884-4895	Acquisition	_
32-4	4896-4899	For	_
32-5	4900-4904	each	_
32-6	4905-4916	participant	_
32-7	4917-4918	,	_
32-8	4919-4926	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-9	4927-4932	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-10	4933-4936	EPI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-11	4937-4938	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-12	4939-4958	echo-planar-imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-13	4959-4960	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-14	4961-4967	images	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-15	4968-4972	were	_
32-16	4973-4981	acquired	_
32-17	4982-4983	;	_
32-18	4984-4994	parameters	_
32-19	4995-5001	varied	_
32-20	5002-5009	between	_
32-21	5010-5013	COS	_
32-22	5014-5017	and	_
32-23	5018-5021	AOS	_
32-24	5022-5026	data	_
32-25	5027-5028	,	_
32-26	5029-5038	including	_
32-27	5039-5043	make	_
32-28	5044-5046	of	_
32-29	5047-5054	scanner	_
32-30	5055-5056	(	_
32-31	5057-5060	see	_
32-32	5061-5066	Table	_
32-33	5067-5069	S1	_
32-34	5070-5073	for	_
32-35	5074-5081	details	_
32-36	5082-5083	)	_
32-37	5084-5085	.	_

Text=T1-weighted anatomical images (MPRAGE) were obtained (voxel size = 0.86×0.86×1.3 mm for COS data, 1×1×1 mm for AOS).
33-1	5086-5097	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-2	5098-5108	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-3	5109-5115	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-4	5116-5117	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-5	5118-5124	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-6	5125-5126	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-7	5127-5131	were	_
33-8	5132-5140	obtained	_
33-9	5141-5142	(	_
33-10	5143-5148	voxel	_
33-11	5149-5153	size	_
33-12	5154-5155	=	_
33-13	5156-5169	0.86×0.86×1.3	_
33-14	5170-5172	mm	_
33-15	5173-5176	for	_
33-16	5177-5180	COS	_
33-17	5181-5185	data	_
33-18	5186-5187	,	_
33-19	5188-5193	1×1×1	_
33-20	5194-5196	mm	_
33-21	5197-5200	for	_
33-22	5201-5204	AOS	_
33-23	5205-5206	)	_
33-24	5207-5208	.	_

Text=2.3 Image Analyses Both COS and AOS fMRI images were analyzed as previously described by our group and as further detailed in Supplemental Methods.
34-1	5209-5212	2.3	_
34-2	5213-5218	Image	_
34-3	5219-5227	Analyses	_
34-4	5228-5232	Both	_
34-5	5233-5236	COS	http://maven.renci.org/NeuroBridge/neurobridge#Glucose
34-6	5237-5240	and	_
34-7	5241-5244	AOS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
34-8	5245-5249	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
34-9	5250-5256	images	_
34-10	5257-5261	were	_
34-11	5262-5270	analyzed	_
34-12	5271-5273	as	_
34-13	5274-5284	previously	_
34-14	5285-5294	described	_
34-15	5295-5297	by	_
34-16	5298-5301	our	_
34-17	5302-5307	group	_
34-18	5308-5311	and	_
34-19	5312-5314	as	_
34-20	5315-5322	further	_
34-21	5323-5331	detailed	_
34-22	5332-5334	in	_
34-23	5335-5347	Supplemental	_
34-24	5348-5355	Methods	_
34-25	5356-5357	.	_

Text=Briefly, preprocessing was done within AFNI using the basic ANATICOR approach and the cleaned, smoothed residual time series were spatially normalized to the Talairach and Tournoux anatomical template.
35-1	5358-5365	Briefly	_
35-2	5366-5367	,	_
35-3	5368-5381	preprocessing	_
35-4	5382-5385	was	_
35-5	5386-5390	done	_
35-6	5391-5397	within	_
35-7	5398-5402	AFNI	_
35-8	5403-5408	using	_
35-9	5409-5412	the	_
35-10	5413-5418	basic	_
35-11	5419-5427	ANATICOR	_
35-12	5428-5436	approach	_
35-13	5437-5440	and	_
35-14	5441-5444	the	_
35-15	5445-5452	cleaned	_
35-16	5453-5454	,	_
35-17	5455-5463	smoothed	_
35-18	5464-5472	residual	_
35-19	5473-5477	time	_
35-20	5478-5484	series	_
35-21	5485-5489	were	_
35-22	5490-5499	spatially	_
35-23	5500-5510	normalized	_
35-24	5511-5513	to	_
35-25	5514-5517	the	_
35-26	5518-5527	Talairach	_
35-27	5528-5531	and	_
35-28	5532-5540	Tournoux	_
35-29	5541-5551	anatomical	_
35-30	5552-5560	template	_
35-31	5561-5562	.	_

Text=Quality of these two datasets was compared using two measures, motion and global signal amplitude, which did not differ across groups (Table S2).
36-1	5563-5570	Quality	_
36-2	5571-5573	of	_
36-3	5574-5579	these	_
36-4	5580-5583	two	_
36-5	5584-5592	datasets	_
36-6	5593-5596	was	_
36-7	5597-5605	compared	_
36-8	5606-5611	using	_
36-9	5612-5615	two	_
36-10	5616-5624	measures	_
36-11	5625-5626	,	_
36-12	5627-5633	motion	_
36-13	5634-5637	and	_
36-14	5638-5644	global	_
36-15	5645-5651	signal	_
36-16	5652-5661	amplitude	_
36-17	5662-5663	,	_
36-18	5664-5669	which	_
36-19	5670-5673	did	_
36-20	5674-5677	not	_
36-21	5678-5684	differ	_
36-22	5685-5691	across	_
36-23	5692-5698	groups	_
36-24	5699-5700	(	_
36-25	5701-5706	Table	_
36-26	5707-5709	S2	_
36-27	5710-5711	)	_
36-28	5712-5713	.	_

Text=After preprocessing, for both COS and AOS data, first we conducted a whole-brain, data-driven search as previously described to identify regions of interest showing connectivity differences, measured by “ connectedness ” (the average Pearson correlation of each voxel with all others) of schizophrenia vs. controls and siblings vs. controls (see details in Supplemental Methods).
37-1	5714-5719	After	_
37-2	5720-5733	preprocessing	_
37-3	5734-5735	,	_
37-4	5736-5739	for	_
37-5	5740-5744	both	_
37-6	5745-5748	COS	_
37-7	5749-5752	and	_
37-8	5753-5756	AOS	_
37-9	5757-5761	data	_
37-10	5762-5763	,	_
37-11	5764-5769	first	_
37-12	5770-5772	we	_
37-13	5773-5782	conducted	_
37-14	5783-5784	a	_
37-15	5785-5796	whole-brain	_
37-16	5797-5798	,	_
37-17	5799-5810	data-driven	_
37-18	5811-5817	search	_
37-19	5818-5820	as	_
37-20	5821-5831	previously	_
37-21	5832-5841	described	_
37-22	5842-5844	to	_
37-23	5845-5853	identify	_
37-24	5854-5861	regions	_
37-25	5862-5864	of	_
37-26	5865-5873	interest	_
37-27	5874-5881	showing	_
37-28	5882-5894	connectivity	_
37-29	5895-5906	differences	_
37-30	5907-5908	,	_
37-31	5909-5917	measured	_
37-32	5918-5920	by	_
37-33	5921-5922	“	_
37-34	5923-5936	connectedness	_
37-35	5937-5938	”	_
37-36	5939-5940	(	_
37-37	5941-5944	the	_
37-38	5945-5952	average	_
37-39	5953-5960	Pearson	_
37-40	5961-5972	correlation	_
37-41	5973-5975	of	_
37-42	5976-5980	each	_
37-43	5981-5986	voxel	_
37-44	5987-5991	with	_
37-45	5992-5995	all	_
37-46	5996-6002	others	_
37-47	6003-6004	)	_
37-48	6005-6007	of	_
37-49	6008-6021	schizophrenia	_
37-50	6022-6025	vs.	_
37-51	6026-6034	controls	_
37-52	6035-6038	and	_
37-53	6039-6047	siblings	_
37-54	6048-6051	vs.	_
37-55	6052-6060	controls	_
37-56	6061-6062	(	_
37-57	6063-6066	see	_
37-58	6067-6074	details	_
37-59	6075-6077	in	_
37-60	6078-6090	Supplemental	_
37-61	6091-6098	Methods	_
37-62	6099-6100	)	_
37-63	6101-6102	.	_

Text=Second, these regions showing reduced connectedness were used as seeds to find the locations driving connectedness differences.
38-1	6103-6109	Second	_
38-2	6110-6111	,	_
38-3	6112-6117	these	_
38-4	6118-6125	regions	_
38-5	6126-6133	showing	_
38-6	6134-6141	reduced	_
38-7	6142-6155	connectedness	_
38-8	6156-6160	were	_
38-9	6161-6165	used	_
38-10	6166-6168	as	_
38-11	6169-6174	seeds	_
38-12	6175-6177	to	_
38-13	6178-6182	find	_
38-14	6183-6186	the	_
38-15	6187-6196	locations	_
38-16	6197-6204	driving	_
38-17	6205-6218	connectedness	_
38-18	6219-6230	differences	_
38-19	6231-6232	.	_

Text=Combining these two sets of regions resulted in one set of all regions that showed differences in functional connectivity between groups.
39-1	6233-6242	Combining	_
39-2	6243-6248	these	_
39-3	6249-6252	two	_
39-4	6253-6257	sets	_
39-5	6258-6260	of	_
39-6	6261-6268	regions	_
39-7	6269-6277	resulted	_
39-8	6278-6280	in	_
39-9	6281-6284	one	_
39-10	6285-6288	set	_
39-11	6289-6291	of	_
39-12	6292-6295	all	_
39-13	6296-6303	regions	_
39-14	6304-6308	that	_
39-15	6309-6315	showed	_
39-16	6316-6327	differences	_
39-17	6328-6330	in	_
39-18	6331-6341	functional	_
39-19	6342-6354	connectivity	_
39-20	6355-6362	between	_
39-21	6363-6369	groups	_
39-22	6370-6371	.	_

Text=Using K-Means cluster analysis on all pairwise correlations, these regions were organized into two clusters, the optimal number as determined by elbow plots and confirmed by silhouette values.
40-1	6372-6377	Using	_
40-2	6378-6385	K-Means	_
40-3	6386-6393	cluster	_
40-4	6394-6402	analysis	_
40-5	6403-6405	on	_
40-6	6406-6409	all	_
40-7	6410-6418	pairwise	_
40-8	6419-6431	correlations	_
40-9	6432-6433	,	_
40-10	6434-6439	these	_
40-11	6440-6447	regions	_
40-12	6448-6452	were	_
40-13	6453-6462	organized	_
40-14	6463-6467	into	_
40-15	6468-6471	two	_
40-16	6472-6480	clusters	_
40-17	6481-6482	,	_
40-18	6483-6486	the	_
40-19	6487-6494	optimal	_
40-20	6495-6501	number	_
40-21	6502-6504	as	_
40-22	6505-6515	determined	_
40-23	6516-6518	by	_
40-24	6519-6524	elbow	_
40-25	6525-6530	plots	_
40-26	6531-6534	and	_
40-27	6535-6544	confirmed	_
40-28	6545-6547	by	_
40-29	6548-6558	silhouette	_
40-30	6559-6565	values	_
40-31	6566-6567	.	_

Text=We examined group differences of region-by-region correlations within- and across-clusters as well as their correlations with clinical measures (SAPS and SANS).
41-1	6568-6570	We	_
41-2	6571-6579	examined	_
41-3	6580-6585	group	_
41-4	6586-6597	differences	_
41-5	6598-6600	of	_
41-6	6601-6617	region-by-region	_
41-7	6618-6630	correlations	_
41-8	6631-6638	within-	_
41-9	6639-6642	and	_
41-10	6643-6658	across-clusters	_
41-11	6659-6661	as	_
41-12	6662-6666	well	_
41-13	6667-6669	as	_
41-14	6670-6675	their	_
41-15	6676-6688	correlations	_
41-16	6689-6693	with	_
41-17	6694-6702	clinical	_
41-18	6703-6711	measures	_
41-19	6712-6713	(	_
41-20	6714-6718	SAPS	_
41-21	6719-6722	and	_
41-22	6723-6727	SANS	_
41-23	6728-6729	)	_
41-24	6730-6731	.	_

Text=ANCOVA models were used to compare groups and examine modulation effects of age-at-onset, medication doses, and clinical measures.
42-1	6732-6738	ANCOVA	_
42-2	6739-6745	models	_
42-3	6746-6750	were	_
42-4	6751-6755	used	_
42-5	6756-6758	to	_
42-6	6759-6766	compare	_
42-7	6767-6773	groups	_
42-8	6774-6777	and	_
42-9	6778-6785	examine	_
42-10	6786-6796	modulation	_
42-11	6797-6804	effects	_
42-12	6805-6807	of	_
42-13	6808-6820	age-at-onset	_
42-14	6821-6822	,	_
42-15	6823-6833	medication	_
42-16	6834-6839	doses	_
42-17	6840-6841	,	_
42-18	6842-6845	and	_
42-19	6846-6854	clinical	_
42-20	6855-6863	measures	_
42-21	6864-6865	.	_

Text=Age and transient Motion were co-varied as nuisance variables in all models and results were corrected using cluster size (AFNI ’ s 3dClustSim, family-wise Type I error (FWE) <.05, employing AFNI ’ s updated spatial auto-correlation function) for whole-brain comparisons and Bonferroni correction for the number of seeds tested.
43-1	6866-6869	Age	_
43-2	6870-6873	and	_
43-3	6874-6883	transient	_
43-4	6884-6890	Motion	_
43-5	6891-6895	were	_
43-6	6896-6905	co-varied	_
43-7	6906-6908	as	_
43-8	6909-6917	nuisance	_
43-9	6918-6927	variables	_
43-10	6928-6930	in	_
43-11	6931-6934	all	_
43-12	6935-6941	models	_
43-13	6942-6945	and	_
43-14	6946-6953	results	_
43-15	6954-6958	were	_
43-16	6959-6968	corrected	_
43-17	6969-6974	using	_
43-18	6975-6982	cluster	_
43-19	6983-6987	size	_
43-20	6988-6989	(	_
43-21	6990-6994	AFNI	_
43-22	6995-6996	’	_
43-23	6997-6998	s	_
43-24	6999-7009	3dClustSim	_
43-25	7010-7011	,	_
43-26	7012-7023	family-wise	_
43-27	7024-7028	Type	_
43-28	7029-7030	I	_
43-29	7031-7036	error	_
43-30	7037-7038	(	_
43-31	7039-7042	FWE	_
43-32	7043-7044	)	_
43-33	7045-7046	<	_
43-34	7047-7050	.05	_
43-35	7051-7052	,	_
43-36	7053-7062	employing	_
43-37	7063-7067	AFNI	_
43-38	7068-7069	’	_
43-39	7070-7071	s	_
43-40	7072-7079	updated	_
43-41	7080-7087	spatial	_
43-42	7088-7104	auto-correlation	_
43-43	7105-7113	function	_
43-44	7114-7115	)	_
43-45	7116-7119	for	_
43-46	7120-7131	whole-brain	_
43-47	7132-7143	comparisons	_
43-48	7144-7147	and	_
43-49	7148-7158	Bonferroni	_
43-50	7159-7169	correction	_
43-51	7170-7173	for	_
43-52	7174-7177	the	_
43-53	7178-7184	number	_
43-54	7185-7187	of	_
43-55	7188-7193	seeds	_
43-56	7194-7200	tested	_
43-57	7201-7202	.	_

Text=More details of data analyses are in Supplemental Methods.
44-1	7203-7207	More	_
44-2	7208-7215	details	_
44-3	7216-7218	of	_
44-4	7219-7223	data	_
44-5	7224-7232	analyses	_
44-6	7233-7236	are	_
44-7	7237-7239	in	_
44-8	7240-7252	Supplemental	_
44-9	7253-7260	Methods	_
44-10	7261-7262	.	_

